Bio-Path pivots to crypto treasury, signs LOI with altFINS, and engages Farrington for biotech asset sale

BIO-PATH HOLDINGS, INC.

Raised $28,659 from Reg A sales of 955,300 shares; authorized 5M Series B Preferred shares convertible into 1,000 common each.
MD Anderson agreed to restart Phase 2 AML trials if Bio-Path pays $292,264 (BP1001) and $63,287 (BP1002) past due.
Issued 22,342 Series B Preferred for Himalaya Technologies (OTC: HMLA) valued at $670,260, making HMLA a majority-owned subsidiary.
Engaged Farrington Capital for exclusive out-license/asset sale of DNAbilize platform and all drug programs; 60-day exclusivity.
Signed LOI with altFINS for Gen2 digital asset treasury; altFINS to receive 2.5M BPTH shares, BPTH gets option to invest €2M at €7.4M valuation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.